The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

And we're really excited to have the Vertex IR team with us ... is a selective NaV1.8 channel inhibitor. So, we're stopping pain where it occurs in the peripheral neurons and because of that we don't ...

The other near-term shot at blockbuster revenues is Vertex's pain therapy, Suzetrigine, a "novel, highly selective Nav1.8 pain signal inhibitor" which Vertex says: has the potential to provide a ...

Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548). BOSTON & SEATTLE, April 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune ...

led by povetacicept and AbbVie-partnered dual CD28 and ICOS inhibitor acazicolcept, which is in a phase 2 lupus trial, with results due later this year. Vertex has built its business on genetic ...

Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, presented the latest data from its eIF4E program at the European Society for Medical Oncology ...

Vertex has been developing inhibitors to the NaV1.8 sodium channel for many years and previously abandoned other candidates because they were not selective enough for the target and inhibited ...

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

Some companies, however, are running programs that are still considered to include active TACE inhibitors, such as those operated by Vertex [38] (thiol-based TACE inhibitors [e.g. compound 10 in ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Insmed (INSM – Research Report), with a price target ...

Thursday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid ...